Bispecific antibody derivatives based on full-length IgG formats

Methods in Molecular Biology

Volumn 901, Issue , 2012, Pages 247-263

  Grote, Michael ^a   Haas, Alexander K ^a   Klein, Christian ^b   Schaefer, Wolfgang ^a   Brinkmann, Ulrich ^a  

^a ROCHE INNOVATION CENTER MUNICH   (Germany)

^b Roche Pharma Research and Early Development   (Switzerland)

Author keywords

Bispecific antibody; CrossMab; Disulfide stabilized Fv antibody fragment (dsFv); Knobs into holes; Single chain variable fragment (scFv)

Indexed keywords

BISPECIFIC ANTIBODY; IMMUNOGLOBULIN G; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANIMAL; ARTICLE; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; PROTEIN ENGINEERING;

ANIMALS; ANTIBODIES, BISPECIFIC; HUMANS; IMMUNOGLOBULIN G; PROTEIN ENGINEERING; SINGLE-CHAIN ANTIBODIES;

EID: 84864148512     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-61779-931-0_16     Document Type: Article

References (51)

1. Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495-497
2. Chames P, Van Regenmortel M, Weiss E, Baty D (2009) Therapeutic antibodies: Successes, limitations and hopes for the future. Br J Pharmacol 157:220-233
3. Chan AC, Carter PJ (2010) Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 10:301-316
4. Weiner LM, Surana R, Wang S (2010) Monoclonal antibodies: Versatile platforms for cancer immunotherapy. Nat Rev Immunol 10:317-327
5. Kontermann RE (2010) Alternative antibody formats. Curr Opin Mol Ther 12:176-183
6. Lu D, Jimenez X, Zhang H et al (2001) Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor. Cancer Res 61:7002-7008
7. Bostrom J, Yu SF, Kan D et al (2009) Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 323:1610-1614
8. Lu D, Zhang H, Ludwig D et al (2004) Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody. J Biol Chem 279: 2856-2865
9. Lu D, Zhang H, Koo H et al (2005) A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem 280:19665-19672
10. Wu C, Ying H, Grinnell C et al (2007) Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol 25:1290-1297
11. Wu C, Ying H, Bose S et al (2009) Molecular construction and optimization of anti-human IL-1alpha/beta dual variable domain immunoglobulin (DVD-Ig) molecules. MAbs 1:339-347
12. Lum LG, Davol PA (2005) Retargeting T cells and immune effector cells with bispecific antibodies. Cancer Chemother Biol Response Modif 22:273-291
13. Behar G, Siberil S, Groulet A et al (2008) Isolation and characterization of anti-FcgammaRIII (CD16) llama single-domain antibodies that activate natural killer cells. Protein Eng Des Sel 21:1-10
14. Muller D, Kontermann RE (2007) Recombinant bispecific antibodies for cellular cancer immunotherapy. Curr Opin Mol Ther 9:319-326
15. Krop IE, Beeram M, Modi S et al (2010) Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 28:2698-2704
16. Burris HA, Rugo HS, Vukelja SJ et al (2011) Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 29:398-405
17. Wu AM, Senter PD (2005) Arming antibodies: Prospects and challenges for immunoconjugates. Nat Biotechnol 23:1137-1146
18. Ronca R, Sozzani S, Presta M, Alessi P (2009) Delivering cytokines at tumor site: The immunocytokine-conjugated anti-EDB- fibronectin antibody case. Immunobiology 214:800-810
19. Kreitman RJ (2006) Immunotoxins for targeted cancer therapy. AAPS J 8:E532-E551
20. Goldsmith SJ (2010) Radioimmunotherapy of lymphoma: Bexxar and Zevalin. Semin Nucl Med 40:122-135
21. Metz S, Haas AK, Daub K et al (2011) Bispecific digoxigenin-binding antibodies for targeted payload delivery. Proc Natl Acad Sci U S A 108:8194-8199
22. Goldenberg DM, Chatal JF, Barbet J et al (2007) Cancer imaging and therapy with bispecific antibody pretargeting. Update Cancer Ther 2:19-31
23. Milstein C, Cuello AC (1983) Hybrid hybridomas and their use in immunohistochemistry. Nature 305:537-540
24. Suresh MR, Cuello AC, Milstein C (1986) Bispecific monoclonal antibodies from hybrid hybridomas. Methods Enzymol 121:210-228
25. Lindhofer H, Mocikat R, Steipe B, Thierfelder S (1995) Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J Immunol 155:219-225
26. Zeidler R, Mysliwietz J, Csanady M et al (2000) The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer 83:261-266
27. Morecki S, Lindhofer H, Yacovlev E et al (2008) Induction of long-lasting antitumor immunity by concomitant cell therapy with allogeneic lymphocytes and trifunctional bispecific antibody. Exp Hematol 36:997-1003
28. Burges A, Wimberger P, Kumper C et al (2007) Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: A phase I/II study. Clin Cancer Res 13:3899-3905
29. Lum LG, Davol PA, Lee RJ (2006) The new face of bispecific antibodies: Targeting cancer and much more. Exp Hematol 34:1-6
30. Repp R, Van Ojik HH, Valerius T et al (2003) Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer. Br J Cancer 89:2234-2243
31. Marvin JS, Zhu Z (2005) Recombinant approaches to IgG-like bispecific antibodies. Acta Pharmacol Sin 26:649-658
32. Muller D, Kontermann RE (2010) Bispecific antibodies for cancer immunotherapy: Current perspectives. BioDrugs 24:89-98
33. Kipriyanov SM, Le Gall F (2004) Recent advances in the generation of bispecific antibodies for tumor immunotherapy. Curr Opin Drug Discov Dev 7:233-242
34. Fischer N, Leger O (2007) Bispecific antibodies: Molecules that enable novel therapeutic strategies. Pathobiology 74:3-14
35. Schirrmann T, Al-Halabi L, Dubel S, Hust M (2008) Production systems for recombinant antibodies. Front Biosci 13:4576-4594
36. Kubetzko S, Balic E, Waibel R et al (2006) PEGylation and multimerization of the antip185HER-2 single chain Fv fragment 4D5: Effects on tumor targeting. J Biol Chem 281:35186-35201
37. Muller D, Karle A, Meissburger B et al (2007) Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J Biol Chem 282: 12650-12660
38. Roopenian DC, Akilesh S (2007) FcRn: The neonatal Fc receptor comes of age. Nat Rev Immunol 7:715-725
39. Demarest SJ, Glaser SM (2008) Antibody therapeutics, antibody engineering, and the merits of protein stability. Curr Opin Drug Discov Dev 11:675-687
40. Bossenmaier B, Brinkmann U, Dormeyer W et al (2010) Bispecific Anti ErbB3/Anti cMet antibodies. Patent no. 120100256339
41. Glockshuber R, Malia M, Pfitzinger I, Pluckthun A (1990) A comparison of strategies to stabilize immunoglobulin Fv-fragments. Biochemistry 29:1362-1367
42. Bird RE, Hardman KD, Jacobson JW et al (1988) Single-chain antigen-binding proteins. Science 242:423-426
43. Huston JS, Mudgett-Hunter M, Tai MS et al (1991) Protein engineering of single-chain Fv analogs and fusion proteins. Methods Enzymol 203:46-88
44. Huston JS, Levinson D, Mudgett-Hunter M et al (1988) Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci U S A 85:5879-5883
45. Reiter Y, Brinkmann U, Lee B, Pastan I (1996) Engineering antibody Fv fragments for cancer detection and therapy: Disulfide-stabilized Fv fragments. Nat Biotechnol 14:1239-1245
46. Jung SH, Pastan I, Lee B (1994) Design of interchain disulfide bonds in the framework region of the Fv fragment of the monoclonal antibody B3. Proteins 19:35-47
47. Reiter Y, Brinkmann U, Jung SH, Pastan I, Lee B (1995) Disulfide stabilization of antibody Fv: Computer predictions and experimental evaluation. Protein Eng 8:1323-1331
48. Ridgway JB, Presta LG, Carter P (1996) 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 9:617-621
49. Schaefer W, Regula JT, Bahner M et al (2011) Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A 108: 11187-11192
50. Sturniolo T, Bono E, Ding J et al (1999) Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat Biotechnol 17:555-561
51. Merchant AM, Zhu Z, Yuan JQ et al (1998) An Efficient route to human bispecific IgG. Nat Biotechnol 16:677-681